The exploration into challenging scenarios of the application of elementary reactions offers excellent opportunities for the development of unique transformations under organometallic catalysis. As a ubiquitous reaction of metal alkyl complexes, β-hydride elimination plays a crucial role in a number of important catalytic transformations. However, its functions in these catalytic cycles are limited
对基本反应应用的挑战性场景的探索为在有机金属催化下发展独特的转化提供了极好的机会。作为金属烷基配合物的普遍反应,β-氢化物消除在许多重要的催化转化中起着至关重要的作用。然而,它在这些催化循环中的功能仅限于释放烯烃产物或通过进一步迁移插入产生异构化中间体。在此,我们报道了 β-氢化物消除的精确操作能够实现自动串联铜催化,用于无向烯基 C-H 键与 CO 2的羧化。在这种转化中,促进了烷基铜中间体的 β-氢化物消除,同时它与 CO 反应2被压制。生成的氢化铜反过来与 CO 2反应,提供多任务催化剂的途径,这使得 C-H 键在两个机械上不同的催化循环中串联硼化/羧化。
Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors
A series of hydroxamic acid-based histone deacetylase (HDAC) inhibitors were designed on the basis of a model of the HDAC2 binding site and synthesized. They are characterized by a cinnamic spacer, capped with a substituted phenyl group. Modifications of the spacer are also reported. In an in vitro assay with the isoenzyme HDAC2, a good correlation of the activity with the docking energy was found. In human ovarian carcinoma IGROV-1 cells, selected compounds produced significant acetylation of p53 and alpha-tubulin. Most compounds showed an antiproliferative activity comparable to that of SAHA. At equitoxic concentrations, the tested compounds were more effective than SAHA in inducing apoptotic cell death. Compounds selected for in vivo evaluation exhibited a significant antitumor activity on three tumor models at well tolerated doses, thus suggesting a good therapeutic index. (C) 2008 Elsevier Masson SAS. All rights reserved.
[EN] MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES MACROCYCLIQUES À LARGE SPECTRE
申请人:RQX PHARMACEUTICALS INC
公开号:WO2017084630A1
公开(公告)日:2017-05-26
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.